Literature DB >> 30048194

Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.

Nick Kontodimopoulos1,2, Eleni Stamatopoulou2, Aikaterini Brinia1, Michael A Talias3, Lara N Ferreira4,5.   

Abstract

BACKGROUND: Systematic discrepancies have been shown in utility values derived from different instruments. This study compares utilities from the condition-specific AQL-5D and the generic EQ-5D-3L and SF-6D in an asthmatic population with heterogeneous health-related quality of life (HRQoL), disease severity, and control status.
METHODS: A consecutive sample of 104 patients diagnosed with asthma completed a survey containing the Greek versions of SF-36, EQ-5D-3L, and AQLQ(s). Treatment adequacy was assessed with the Asthma Control Questionnaire (ACQ), and asthma severity according to Global Initiative for Asthma 2016 guidelines. Association and agreement between instruments were assessed with Spearman's correlation and Bland-Altman plots.
RESULTS: AQL-5D utilities exceeded (p < 0.001) those from EQ-5D-3L and SF-6D. There were weak-to-moderate correlations (<0.5) between most dimensions of AQL-5D, and those of EQ-5D-3L and SF-6D, and strong correlations between similar dimensions of EQ-5D-3L and SF-6D. Significant differences (p < 0.001) were observed throughout the visual analog scale (VAS), asthma severity and asthma control subgroups, with AQL-5D consistently higher than EQ-5D-3L and SF-6D.
CONCLUSIONS: All instruments distinguished between differing degrees of asthma control, but only AQL-5D discriminated between asthma severity and HRQoL as well. Although the relatively small sample warrants caution in interpreting the subgroup results, this study contributes to the growing number of comparisons between condition-specific and generic preference-based instruments.

Entities:  

Keywords:  AQL-5D; Asthma; EQ-5D-3L; SF-6D; Utilities

Mesh:

Year:  2018        PMID: 30048194     DOI: 10.1080/14737167.2018.1505506

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  4 in total

Review 1.  Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review.

Authors:  Joseph W Lanario; Lorna Burns
Journal:  J Asthma Allergy       Date:  2021-08-12

2.  Challenges in synthesising cost-effectiveness estimates.

Authors:  Gemma E Shields; Jamie Elvidge
Journal:  Syst Rev       Date:  2020-12-09

3.  A Comparison of EQ-5D-3L, EQ-5D-5L, and SF-6D Utilities of Patients with Musculoskeletal Disorders of Different Severity: A Health-Related Quality of Life Approach.

Authors:  Nikolaos Kontodimopoulos; Eleni Stamatopoulou; Sousana Gazi; Dimitra Moschou; Michail Krikelis; Michael A Talias
Journal:  J Clin Med       Date:  2022-07-15       Impact factor: 4.964

4.  The health‑related quality of life of patients with musculoskeletal disorders after the COVID‑19 pandemic.

Authors:  Gen-Ying Zhu; Di Zhu
Journal:  Int Orthop       Date:  2022-09-13       Impact factor: 3.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.